Despite the availability of several treatment options for asthma, some individuals may still have difficulty controlling their symptoms.
The FLASH study aims to assess efficacy and safety of multiple dose levels of Atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled Asthma.
Participant eligibility criteria
- Male and female participants between 18 to 55 years of age
- Confirmed asthma diagnosis ≥ 12 months prior to screening
- Able to perform acceptable lung function testing
